Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 4Thyroid Carcinoma, Anaplastic 3Neoplasms 3Glioma 3Recurrence 2Neurofibromatosis 1 2Neoplasm Metastasis 2Multiple Myeloma 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Thyroid Neoplasms 1Solid Tumor Cancer 1Solid Tumor 1Skin Neoplasms 1Sexual Dysfunction, Physiological 1Refractory Differentiated Thyroid Gland Carcinoma 1Rare Malignant Neoplasm 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Oligodendroglioma 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Leukemia, Myelomonocytic, Juvenile 1

Interventions

Cyclophosphamide 8fludarabine 6cabozantinib 5Temozolomide 4Doxorubicin 4Zoledronic Acid 3X-Rays 3Vincristine 3Methotrexate 3Ifosfamide 3Gemcitabine 3Cisplatin 3irinotecan sucrosofate 2atezolizumab 2Surgical Procedures, Operative 2Sunitinib 2Specimen Handling 2Radiosurgery 2Phantoms, Imaging 2Mesna 2Magnetic Resonance Spectroscopy 2Irinotecan 2Eflornithine 2Disulfiram 2Biopsy 2vactosertib 1trilaciclib 1trametinib 1talazoparib 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Osteosarcoma × trametinib × Clear all
NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
45 enrolled
Sarcoma

Neoplasm Metastasis, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡